US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

21.51

-0.1100-0.51%

Volume:708

Turnover:15.22K

Market Cap:4.30M

PE:- -

High:21.54

Open:21.54

Low:21.51

Close:21.62

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:2.54

T/O Rate:0.35%

Dividend:0.08

Dividend Rate:0.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy

MT Newswires Live

Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings

CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Press Release: Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Press Release: Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IND/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":21.51,"timestamp":1790871777185,"preClose":21.62,"halted":0,"volume":708,"delay":0,"changeRate":-0.005087881591119308,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Trading","change":-0.11,"latestTime":"10-01 12:29:34 EDT","open":21.54,"high":21.54,"low":21.51,"amount":15222.27612,"amplitude":0.001388,"askPrice":21.53,"askSize":100,"bidPrice":21.36,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":21.62,"sharesOutstanding":200001,"nav":21.568,"aum":4313687.26,"dividendRate":0.003673,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.67,"preClose":21.62,"latestTime":"16:10 EDT","volume":7,"amount":151.34,"timestamp":1790799005077,"change":0.05,"changeRate":0.002313,"amplitude":0},"volumeRatio":2.537215},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.537215,"shares":200001,"dividePrice":0.079,"high":21.54,"amplitude":0.001388,"preClose":21.62,"low":21.51,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":21.51,"committee":0.5,"eps":0,"divideRate":0.003673,"volume":708,"delay":0,"ttmEps":0,"open":21.54,"prevYearClose":24.78,"prevWeekClose":22.3,"prevMonthClose":21.62,"prevQuarterClose":21.62,"fiveDayClose":22.15,"twentyDayClose":23.255,"sixtyDayClose":22.825},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658952506","title":"Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952506","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952506?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342215/0/en/fractyl-health-reports-second-quarter-2026-financial-results-and-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JDOC","GUTS","BK4082","CTA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995628","title":"Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995628?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:01","pubTimestamp":1786392060,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data. -- Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO. -- Announced a clinical trial collaboration and supply agreement with Bayer. to evaluate darolutamide in combination with OP-3136 in metastatic. -- Ended the second quarter with $461.1 million in cash, cash equivalents,palazestrant as a monotherapy in patients with second or third-line. estrogen receptor-positive (ER+), human epidermal growth factor receptor. -- Presented initial Phase 1 clinical data for OP-3136 as a monotherapy in. multiple solid tumor types and a trial-in-progress poster for the pivotal. Phase 3 OPERA-02 trial evaluating palazestrant in combination with. ribociclib in frontline ER+/HER2- MBC at the 2026 American Society of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","MBC","HYLG","GDOC","IDNA","OP.USD.HKCC","NVIB","BK4086","IND","MEDX","OLMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658953571","title":"NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2658953571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658953571?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:34","pubTimestamp":1786372440,"startTime":"0","endTime":"0","summary":"Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma could mark a Major Clinical Catalyst for NeOncDENVER, Aug.  10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) –NeOnc Technolog","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341958/0/en/neonc-heads-into-a-high-stakes-week-as-highly-anticipated-neo100-phase-2a-data-readout-nears.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","NTHI","BK4007","BBB","IND","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993909","title":"Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993909","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993909?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366860,"startTime":"0","endTime":"0","summary":"Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceAppointment further streng","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4581","BK4585","LENZ","BK4139","BK4233","BK4588","SYNB","XBI","BK4007","IND","BBP","IBB","BK4205","BK4539","RFL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658493102","title":"NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658493102","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658493102?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:30","pubTimestamp":1786365000,"startTime":"0","endTime":"0","summary":"Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern TimeCALABASAS, Calif., Aug.  10, 2026  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341823/0/en/neonc-technologies-to-host-investor-conference-call-to-discuss-topline-phase-2a-results-for-intranasal-neo100-in-recurrent-idh1-mutant-high-grade-glioma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IND","HST","IDNA","BMED","NVIB","BK4588","CNS","BK4181","BK4218","GDOC","MEDX","BK4135","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936649","title":"Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936649","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936649?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.MIAMI, Aug.  10, 2026  (GLOBE NEWSWIRE) ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341757/0/en/telomir-announces-peer-reviewed-publication-demonstrating-telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","IND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936592","title":"Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936592?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341783/0/en/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","LU0124384867.USD","LU1861215975.USD","BK4512","BK4605","LU2298322129.HKD","IE00BFMHRM44.USD","LU1861220033.SGD","LU1670628061.USD","LU1861214812.USD","LU1983260115.SGD","LU1854103824.USD","IE00BZ199S13.USD","BK4089","LU0724618433.USD","LU1548497426.USD","LU1854104046.USD","LU1978683503.SGD","LU1720051017.SGD","BK4141","LU1670627923.USD","BK4585","LU2360107325.USD","LU1720051108.HKD","IND","BK4532","ON","LU2357305700.SGD","LU1861219969.SGD","IE00BD6J9T35.USD","BK4588","CCOI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936984","title":"Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359600,"startTime":"0","endTime":"0","summary":"Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481011671.HKD","LXRX","PBE","BK4504","KBWP","KBWB","LU0971096721.USD","PGR","LU0912757837.SGD","IE00B775H168.HKD","LU1718418525.SGD","IE00BZ1G4Q59.USD","NVIB","LU1366192091.USD","IE0005OL40V9.USD","LU1035773651.USD","NBIX","IAI","UBCP","BK4596","QNTM","LU2089284900.SGD","IE0004445015.USD","LCDL","LU0320765992.SGD","LU2087625088.SGD","CAGR","LU2065170008.USD","IAK","BNDI","BK4099","LU1988902786.USD","BK4007","IE00BN29S564.USD","LU0070302665.USD","LU1668664300.SGD","IND","BK4532","BMED","LU0772969993.USD","LCIZ","LCID","LU0731783394.SGD","BK4516","BK4139","BIIB","LU0889565916.HKD","LU0053666078.USD","LABU","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626861","title":"Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626861?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"In June 2026, Entera announced that the FDA accepted Entera's plan to. conduct a single, randomized, double-blind, placebo-controlled Phase 3. trial in approximately 750 postmenopausal women with osteoporosis, with a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","KOL","LU1169589451.USD","LU1169590202.USD","BK4218","PK","BK4023","BK4022","BK4139","ENTX","PD","KBWY","R","BK4232","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610803","title":"Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610803?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":"Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)Full year 2026 revenue guidance of $100.5 to $111.0 million affirmedNDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","LU1223083913.SGD","BK4023","CDE","LU1169590202.USD","SGDM","CFO","CHB","PD","LU1223082196.USD","GYRE","BK4588","BK4555","BK4099","BK4585","03160","IND","CEO","LU1223082519.USD","TM","XME","BK4139","SIL","BK4604","GDXJ","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657226618","title":"CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2657226618","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657226618?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:38","pubTimestamp":1786088298,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  said its investigational new drug application for CT1190B, an allogeneic CAR T-cell therapy targeting CD19/CD20, received clearance from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The clearance allows the company to begin a clinical trial of CT1190B in patients with relapsed or refractory large B-cell lymphoma who have failed at least two prior lines of standard therapy.z","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1585","BK4539","BK1161","BK1574","IND","BK1587","02171","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657366055","title":"Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2657366055","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657366055?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:40","pubTimestamp":1786066858,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics’ Q2 2026 results showed a wider net loss of $12.9 million, or $0.11 per diluted share, as research and development expense nearly tripled to $8.4 million. Quarterly operating cash outflow increased to $9.6 million from $6.4 million, while cash, cash equivalents and short-term investments totaled $217.7 million at June 30. Management expects those resources to fund operations through 2029, including completion of NDV-01’s Phase 3 RESCUE program, as both lead programs move toward planned year-end 2026 IND filings.","market":"us","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock7.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock7.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262086730-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GXDW","LRND","VOTE","FEBU","RGLO","JOYT","PMDE","IND","VGFPF","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147606546","title":"CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1147606546","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147606546?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:12","pubTimestamp":1786061532,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).This \"off-the-shelf\"...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1587","BK1574","BK1585","BK1161","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657969399","title":"Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657969399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657969399?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipate","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340707/0/en/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661492","title":"Oculis Reports Q2 2026 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661492","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661492?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, Aug.  06, 2026  (GLOBE NEWSWIRE) -- Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program wit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340699/0/en/Oculis-Reports-Q2-2026-Financial-Results-and-Provides-Company-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","LU0106261372.USD","LU0124384867.USD","LU1861215975.USD","BK4512","LU0795875086.SGD","LU1244550221.USD","LU2111349929.HKD","BK4605","IAI","LU0267386448.USD","LU1988902786.USD","LU1989772923.USD","LU2298322129.HKD","LU2271345857.HKD","LU1074936037.SGD","LU0158827948.USD","BK4534","LU1064131342.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","KBWB","LU1861220033.SGD","LU1983260115.SGD","LU1363072403.SGD","LU1854103824.USD","IE00BZ199S13.USD","LU1732799900.SGD","LU2487616109.SGD","LU0320765646.SGD","LU1548497426.USD","LU1854104046.USD","LU0971096721.USD","LU0210528500.USD","BK4504","BK4141","LU2133065610.SGD","LU0528227936.USD","LU1732800096.USD","IND","LU0234570918.USD","LU1244550577.SGD","ON","LU1668664300.SGD","LU1861219969.SGD","LU2089284900.SGD","BK4588","OCS","LU1791710582.SGD","LU1244550494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","CMC","LU2041044095.USD","LU2229751404.USD","LU1721429402.USD","LU2092937221.SGD","LU1721428933.USD","LU2237443622.USD","IE00BFXG1179.USD","A","LU2413666699.HKD","LU2746668974.SGD","R","LU0149725797.USD","ALLO","BK4232","IE00BHPRN162.USD","LU0971096721.USD","LU0882574139.USD","IND","BK4006","PWS","BK4539","LU2237443549.SGD","BK4007","IE00BN0W2V16.EUR","BK4588","LU1721429741.USD","BK4567","PSIL","LU2089279066.USD","LU2746668461.USD","IE00B1BXHZ80.USD","LU2413666426.HKD","IE00BN0W2T93.GBP","BK4505","IE00BZ1G4Q59.USD","LU0170899867.USD","BK4585","LENZ","IE00BN0W2W23.USD","RLMD","EES","LU1543694498.USD","BK4139","LU2237443465.HKD","LU0347712357.USD","LU2237443895.HKD","LU2237443978.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963672","title":"Press Release: Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963672","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657963672?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017660,"startTime":"0","endTime":"0","summary":"-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","DBMF","ISMF","PRME","BK4093","LU0630314457.HKD","BK4195","VEGI","LU0345780950.USD","BK4588","BK4229","BK4585","CTA","BK4139","TFPN","CF","LABU","JPFP","LU0345781412.USD","SDMF","WD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636277","title":"Press Release: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636277?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"financing. The financing included participation from existing investors. including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1. Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus,as well as members of Whitehawk's executive team.-- Continued to enroll patients into ongoing Phase 1 trials for HWK-007 and. -- HWK--007 is being evaluated in patients with non-squamous, EGFR. cancer; and endometrial cancer . The study design was. presented as a Trials-in-Progress poster at the American Society. -- Entered into a new option agreement with Hangzhou DAC for access to. CPT113 for use in up to five additional ADC programs. Whitehawk's ADC. platform leverages CPT113 as the core linker-payload technology, adding. bioconjugation process to support improved stability and therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","IND","BK4022","LENZ","R","NETL","BK4139","BK4539","ADC","BK4232","BK4080","BK4231","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680722","title":"Press Release: Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680722?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"-- Plans to initiate a registrational Phase 3 program evaluating abdakibart. in hidradenitis suppurativa  in the first half of 2027. -- Expanded pipeline with AVTX-010, a long-acting next-generation. anti-IL-1<BETA> antibody, with IND submission planned for the first half. -- Cash, cash equivalents and investments of $472.2 million as of June 30,abdakibart in HS in the first half of 2027.HS as well as other inflammatory disorders. The Company expects to submit. an Investigational New Drug  application in the first half of 2027.-- Appointed Ron Philip to its Board of Directors. Ron contributes deep. strategic and commercial expertise, with a proven track record of. -- Added to the Russell 2000 and Russell 3000 Indexes as part of the. 2026. Net cash used in operating activities was $37.7 million for the six. months ended June 30, 2026. Avalo's current cash, cash equivalents, and. investments are expected to fund operations into 2029.-- Research and development expenses were $23.4 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AVTX","BK4007","LENZ","R","BK4022","BK4232","IND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638343","title":"Press Release: Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638343","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638343?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"--  Last participant completed final study visit in the 16-week. double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in. post-bariatric hypoglycemia; topline data on track and anticipated in. CAMBRIDGE, Mass.----August 06, 2026--Amylyx Pharmaceuticals, Inc.   today reported financial and business results for the second quarter ended June 30, 2026.\"With the last participant's final study visit recently completed, we are eagerly anticipating the expected topline data readout of the pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia in late August or early September,\" said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. \"In parallel, we are continuing to advance our NDA readiness and our pre-commercial work to support a potential submission and commercial launch of avexitide in 2027, if approved. At ENDO in June 2026, we activated our disease state education campaign, 'Uncover the Mystery of Post-Bariatric Hypoglycemia,' designed to increase awareness and un","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","PBH","ASO","BK4007","IND","BK4200","BK4561"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}